TGFB2 and neoplasm: OT101 (also known as trabedersen), a TGFβ2-specific synthetic antisense oligodeoxynucleotide (S-ODN), is a first-in-class RNA therapeutic with a Food and Drug Administration (FDA) orphan drug designation (ODD) and pediatric rare disease designation, that is designed to abrogate the tumor-promoting and immunosuppressive actions of TGFβ2 [16,17,25,26].